The #PALAVY trial Penn Medicine - Abramson Cancer Center aims to lower recurrence risk by enrolling Stage II or III ER+ & HER2- breast cancer survivors on at least 2 years of endocrine therapy. Step 1 screens for DTCs in the bone marrow, while step 2 offers targeted treatment. #ClinicalTrials #BCSM

Cancer drug shortages should not be a political issue. @senbobcasey Join your colleagues in the House and Senate to swiftly mitigate widespread cancer #drugshortages . Patients’ lives are at stake. #ASCOAdvocacy

New Journal of the @NCCN by Jeff Shevach DCI Center for Prostate & Urologic Cancers, Kara Maxwell & me Penn: Disparities in precision #oncology arise from disparities in access. We find Black-White disparities in germline testing for men with commercial insurance, NOT equal-access Veterans Affairs jnccn.org/view/journals/…

Scenes from #ASCOAdvocacySummit where we’re urging Congress to help end #drugshortages , support robust federal research funding, and expand telehealth. Inspired by the unwavering dedication of our advocates.

Add your voice using the ASCO ACT Network: ASCO.org/ACTnetwork

Busy couple of days on the Hill at @asco advocacy summit. Advocating for telehealth, fixes for drug shortages, & @nih National Cancer Institute funding. Jessica Hawley MD MS Robin Zon DrBlairIrwin Rep. Kim Schrier, M.D.

Did as Dr. Kimryn Rathmell Dr. Rathmell said. Met new colleagues and we watched the eclipse together AACR Chinyere Chambers Gloria Asantewaa and with my long standing friend and colleague Angie DeMichele, MD, MSCE, FASCO

Thank you to AACR for giving me the opportunity to present. It was a wonderful experience! #AACR24

The 2-PREVENT TCE MRD specific trials are focused on monitoring, detecting, & treating MRD in order to prevent metastatic breast cancer. The entire month of April we will be highlighting all our active and enrolling trials! #BCSM #ClinicalTrials

Listen to the latest ASCO podcast where Dr. Angela DeMichele (@AngieDemichele), Dr. Lynn Henry, and Dr. Harold Burstein (@DrHBurstein) discuss the rapid guideline update on endocrine and targeted therapy for HR+, HER2+ #MetastaticBreastCancer
Listen here:
ascopubs.org/doi/pdf/10.120…

Couldn’t be more thrilled to be part of The exciting science, learning , camaraderie and not to forget the FUN ASCO scientific committee with ⭐️ Patrick Forde Shankar Siva Melina Marmarelis Lecia Sequist, MD, MPH Jarushka Naidoo and #ASCO24 leadership ASCOPres Angie DeMichele, MD, MSCE, FASCO Erika Hamilton, MD

What a team! @asco Scientific Program and Education Committee Leadership working on pulling together another fantastic annual meeting. ASCOPres Clifford Hudis Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Erika Hamilton, MD Kimmie Ng, MD, MPH Angie DeMichele, MD, MSCE, FASCO Cardinale B. Smith

Congratulations to our co-director Angie DeMichele, MD, MSCE, FASCO for her work as ASCO Scientific Program Committee Chair at HQ this week. Next up, the annual meeting in Chicago in June. Can’t wait! #ASCO2024

New ASCO Rapid Guideline Update for Endocrine and Targeted Therapy for Hormone Receptor - Positive, Human Epidermal Growth Factor Receptor 2 - Negative #MetastaticBreastCancer - Capivasertib - Fulvestrant.
Harold J. Burstein, MD, PhD, FASCO Angie DeMichele, MD, MSCE, FASCO Lesley Fallowfield
ascopubs.org/doi/pdf/10.120…

Such phenomenal energy, collaboration & dedication at ASCO HQ for the #ASCO24 Scientific Program and News Planning Committee meetings. A truly vibrant & dynamic program is in store. Be sure to join us in Chicago May 31-June 4: am.asco.org

I couldn’t be more impressed with the leadership of Lynn M. Schuchter, MD, FASCO, Angie DeMichele, MD, MSCE, FASCO, & Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO - #ASCO24 is going to be a great meeting! Thank you to all of the volunteers for the countless hours of work on behalf of @asco! See you in Chicago! Dana-Farber

Empower your journey 🌟Exploring clinical trials for breast cancer treatment can sometimes feel like a difficult task. At Penn Medicine - Abramson Cancer Center you’re not alone- our clinical trial navigation team is here to guide you every step of the way! #clinicaltrialaccess #BCSM

New study identifying breast cancer metastatic driver mutations published by Penn Medicine - Abramson Cancer Center 2-PREVENT breast cancer TCE investigators Drs Lewis Chodosh & Angie DeMichele, MD, MSCE, FASCO and team in Genome Medicine. Univ. of Pennsylvania Department of Cancer Biology Penn Medicine

shorturl.at/egE15

The 2-PREVENT Breast Cancer TCE at Penn Medicine tackles relapse head-on. By monitoring and treating minimal residual disease, we’re redefining survivorship. Empowering patients and enhancing access to clinical trials, we’re committed to making a difference! #BCSM

I had the honor of sitting down with Breastcancer.org to talk about the CLEVER study, breast cancer recurrence, and what the next steps are. Check out the podcast here breastcancer.org/podcast/treati…

Study Chair Nadine Tung MD of BIDMC explains research study EA1181/CompassHER2 pCR, which aims to optimize the amount of chemotherapy patients with HER2-positive #breastcancer receive. cc: Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) Angie DeMichele, MD, MSCE, FASCO #bcsm